S
Sandra Peake
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
Sep 29, 2026
ARISE-FLUIDS Trial Presentation
49:07
49:11
49:25
49:34

Sandra PeakeGUEST
I won't spend a lot of time because I think I'd rather have discussions around everything.

Sandra PeakeGUEST
I'll just really focus on the things which I think were also particularly important and that was around the primary outcome and the effect size.

Sandra PeakeGUEST
So as you alluded to, we had done some earlier observational work around patients coming to the ED with septic shock.

Sandra PeakeGUEST
And we found that in Australia and New Zealand, our mortality is less than 10%.
5 MINS LATER
S
54:56speaker_7UNKNOWN
And that goes on to then that if they'd already received this fluid resuscitation, does a litre difference in the first six hours or 24 hours really make a difference? Or do we really think that that would make a significant difference in terms of patient outcomes?
